COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00051597
Recruitment Status : Completed
First Posted : January 15, 2003
Last Update Posted : October 12, 2011
Information provided by:
Seagen Inc.

Brief Summary:

The purpose of this study is to evaluate a multi-dose regimen of SGN-30, a novel chimeric monoclonal antibody (mAb), in patients with refractory or recurrent CD30+ hematologic malignancies.

This is a single-arm, open-label phase I/II study designed to define the toxicity profile, pharmacokinetic (PK) profile, and anti-tumor activity of a multi-dose regimen of SGN-30 in patients with refractory or recurrent CD30+ hematologic malignancies. The phase I study will be a modified dose escalation of SGN-30. Based on preclinical pharmacology and toxicokinetics (TK) and the first use in human single-dose phase I study, SGN-30 will be administered on a weekly schedule. An initial dose of 2 mg/kg will escalate until the maximum tolerated dose (MTD) has been reached or until a weekly dose of 12 mg/kg is achieved.

Condition or disease Intervention/treatment Phase
Hodgkin Disease Lymphoma, Large-Cell Sarcoma, Kaposi Lymphoma, T-Cell, Cutaneous Lymphoma, B-Cell Drug: SGN-30 (monoclonal antibody) Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 70 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Multi-Dose Study of SGN-30 in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
Actual Study Completion Date : August 2003

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


Histologically confirmed CD30+ hematologic malignancy. Immunohistochemistry or flow cytometry may be performed on either original diagnostic biopsy material or biopsy of relapsed disease.

Patients must have at least one of the following:

  • Patients with HD must have failed systemic chemotherapy either as initial therapy for advanced stage disease or as salvage therapy after initial radiotherapy (XRT) for early stage disease and be ineligible for, or refuse treatment by stem cell transplantation
  • Patients with other CD30+ malignancies must be beyond 1st remission or refractory to front line chemotherapy
  • Patients with refractory or chemo-resistant multiple myeloma (MM), as defined by a failure to respond (<50% reduction in M-protein level), or disease progression less than 2 months after receiving at least two conventional chemotherapy regimens
  • Patients with MM in the Plateau Phase of their disease may be included in the study. Plateau phase will be defined as persistent (more than 6 weeks) M-protein in the serum or urine despite a significant initial reduction (>50%) in response to previous therapy. These patients should have received at least two of the conventional chemotherapy regimens listed above prior to enrollment in this study.
  • Patients with relapsed MM as defined by disease progression more than 2 months after initial therapy and subsequent failure to respond (<50% reduction or progression in M-protein levels) to ONE of the above listed regimens or other salvage regimens (high dose cyclophosphamide, topotecan).

Patients must have at least one of the following:

  • Bidimensional or unidimensional measurable disease on physical examination or radiologic evaluation
  • Circulating tumor cells in peripheral blood
  • Evidence of bone marrow disease to any degree in patients with HD
  • >10% tumor cells in bone marrow in patients with other CD30+ malignancies
  • Minimum of 4 weeks from last therapy (including radiotherapy or chemotherapy); a minimum of 6 weeks from last treatment with nitrogen mustard agents, melphalan or BCNU
  • ECOG performance status ≤ 2 (Appendix B) with a life expectancy > 3 months


  • A diagnosis of Cutaneous T-Cell Lymphoma (CTCL) or non-secretory MM
  • Symptomatic cardiac disease including ventricular dysfunction, coronary artery disease or arrhythmias
  • More than one primary malignancy with the exception of non-melanoma skin cancer or cervical carcinoma in situ (CIN) on a biopsy or squamous intraepithelial lesion (SIL) on PAP smear
  • Active viral, bacterial, or systemic fungal infection including known HIV positivity
  • Symptomatic brain metastases requiring treatment
  • Concurrent therapy with other anti-neoplastic agents, corticosteroids, or experimental agents
  • Any serious underlying medical condition which would impair the ability of the patient to receive or tolerate the planned treatment including prior allergic reactions to recombinant human or murine proteins
  • Receipt of any therapeutic mAbs within 6 months unless a recent serum testing reveals no antibody titer and no evidence of anti-chimeric or anti-murine antibody in the peripheral circulation
  • Female patients who are pregnant or breastfeeding
  • Dementia or altered mental status that would prohibit the understanding and rendering of informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00051597

Layout table for location information
United States, Alabama
University of Alabama, Birmingham
Birmingham, Alabama, United States, 35294
United States, California
USC Norris Cancer Center
Los Angeles, California, United States, 90033
United States, Florida
University of Miami
Miami, Florida, United States, 33136
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, Missouri
Siteman Cancer Center
St. Louis, Missouri, United States, 63110
United States, Nebraska
University of Nebraska
Omaha, Nebraska, United States, 68198
United States, New York
Cornell Medical College, New York Presbyterian
New York, New York, United States, 10021
University of Rochester
Rochester, New York, United States, 14642
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Washington
University of Washington
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Seagen Inc.
Layout table for investigator information
Study Director: Amy P Sing, MD Seagen Inc.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00051597    
Other Study ID Numbers: SG030-0002
First Posted: January 15, 2003    Key Record Dates
Last Update Posted: October 12, 2011
Last Verified: October 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma, Kaposi
Hematologic Neoplasms
Hodgkin Disease
Lymphoma, B-Cell
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms, Connective and Soft Tissue
Neoplasms by Site
Hematologic Diseases
Lymphoma, Non-Hodgkin
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Neoplasms, Vascular Tissue
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs